INTRODUCTION
The yeast proteins Sup35p and Ure2p, which have been proposed as being responsible for the phenotypes [PSI + ] and [URE3] (Wickner, 1994) , are highly tractable models for understanding the mechanism underlying prion propagation. It has been clearly demonstrated by a number of groups that the [PSI + ] phenotype is associated with the aggregation and consequent non-functionality of Sup35p. The salient observations are as follows.
(i) Upon transition to its prion form, Sup35p is significantly depleted from a 100 000 g supernatant after centrifugation of a yeast extract. However, Sup35p is largely soluble under the same experimental conditions when the extract is made from a [psi -] strain (Patino et al., 1996; Paushkin et al., 1996 Paushkin et al., , 1997 . The prion state, as defined by the [PSI + ] phenotype, thus correlates with a dramatic change in the solubility of the protein.
(ii) A fusion between the SUP35 and GFP genes demonstrate that a chimeric Sup35p-GFP protein aggregates in the cytoplasm of [PSI + ] yeast strains but not in otherwise isogenic [psi -] strains (Patino et al., 1996) . Furthermore, this aggregation is, as for the [PSI + ] phenotype, dependent upon the activity of the molecular chaperone Hsp104 (Chernoff et al., 1995) .
(iii) Sup35p purified following heterologous expression in Escherichia coli can self-assemble to form amyloid fibres (Glover et al., 1997; King et al., 1997) .
(iv) Crude cell-free extracts made from [PSI + ] yeast strains induce very efficient Sup35p polymerization in vitro (Glover et al., 1997; Paushkin et al., 1997) .
(v) A mutation in the SUP35 gene, originally isolated and described as the PNM2 allele (Doel et al., 1994) , inhibits [PSI + ] propagation and encodes a protein that is poorly converted in vitro to the amyloid form (Kochneva-Pervukhova et al., 1998) .
The molecular behaviour of the [URE3] determining protein Ure2p is less clear. In vitro, purified recombinant Ure2p protein forms a dimer (Perrett et al., 1999) , while Thual et al. (1999) showed that the Ure2p protein can also be found as monomeric, dimeric and tetrameric forms. The ability of Ure2p to selfassociate was confirmed by two-hybrid studies (FernandezBellot et al., 1998) . Interestingly, purified Ure2p behaves in a similar manner to Sup35p in spontaneously forming amyloid fibrils in vitro (Thual et al., 1999) . The prion domain of Ure2p is sufficient to promote such polymerization in trans (Taylor et al., 1999) , but also in cis when linked to the glutathione S-transferase moiety (Schlumpberger et al., 2000) . Ure2p appears to be slightly more resistant to proteinase K in a [URE3] strain (Masison and Wickner, 1995) . In vivo, studies with URE2-GFP fusions demonstrate a large, visible aggregation of Ure2p in a [URE3] but not a [ure3°] derivative of the strain YHE64 (Edskes et al., 1999) . These data are consistent with a prion mechanism in which the [URE3] determinant would be a highly aggregated form of Ure2p.
scientific report
In this communication, we present new data on the nature of the [URE3] determinant that lead us to propose an alternative model in which the prion form of Ure2p is found in a soluble state rather than in a highly aggregated state.
RESULTS

Ure2p does not form large aggregates in [URE3] strains
We constructed a yeast strain, EG12, which is suitable for genetic analysis because the URE2-GFP fusion is inserted at the URE2 locus. After plating on a selective medium containing ureidosuccinate (USA), one Usa + clone was analysed in depth. The Usa + phenotype could be reversed in the presence of millimolar concentration of guanidine hydrochloride, as expected for a yeast prion determinant. Furthermore, the Usa + phenotype of the isolated spores was transmitted in a dominant way by mating. Following meiosis, this diploid gave rise to tetrads that showed the characteristic non-Mendelian segregation of the [URE3] phenotype (Aigle and Lacroute, 1975 (Edskes et al., 1999) , the specific aggregation pattern previously observed with another plasmid was found (Figure 1 ). However, in the EG12 [URE3] strain, we still observed an even fluorescence with no evidence of foci (Figure 1 ). The Ure2p-GFP construct used in this study was capable, therefore, of producing detectable clumps, as are previously described Ure2p-GFP constructs.
Ure2p can aggregate in wild-type cells
In vitro, Ure2p can polymerize in a concentration-dependent manner (Thual et al., 1999) . Therefore, we explored the relationship between the level of expression and the aggregation, in vivo, of the Ure2p protein using the Ure2p-GFP fusion.
Several clones obtained with the multi-copy plasmid pYeHFc 2L V10 URE2-GFP, and verified as having a wild-type Usaphenotype with respect to the [URE3] determinant, were analysed. Surprisingly, the majority of the cells viewed had large Ure2p-GFP aggregates in their cytoplasm ( Figure 2A ). In some cases, two distinct types of aggregate appeared to coexist in the cytoplasm (Figure 2A , insert).
The degree of aggregation of the Ure2p-GFP was enhanced in stationary phase cells, where the majority of cells contain visible aggregates ( Figure 2B ); in the exponential-phase cells, only ∼10% of the cells contained aggregates (Figure 2A ). In stationary phase cells, no aggregates could be observed in the non-transformed [URE3] EG12 strain (data not shown).
The Ure2p prion-forming domain enhances the aggregation
When overexpressed, the N-terminal domain of Ure2p strongly increases the rate of [URE3] formation (Masison and Wickner, 1995) . When overexpressed in the EG12 strain, the N-terminal domain of Ure2p increased the rate of [URE3] appearance 1000-fold. The frequency of Usa + clones found under these conditions was ∼10 -3 . However, the transformed cells do not show any differences in the pattern of GFP fluorescence ( Figure  3A ). Isolated [URE3] clones were examined for evidence of protein aggregation. Interestingly, the typical pattern of GFP aggregation was only occasionally observed in these cells. However, the majority of cells that formed a given clonal population did not contain any aggregates ( Figure 3B ). The presence of the prion isoform does not affect the Ure2p solubility
We next examined the level of Ure2p aggregation in total cellfree lysates using a differential centrifugation assay. As a control, scientific report we also tested the solubility of Sup35p, the prion determinant of the [PSI + ] phenotype. To allow for direct comparability between the aggregation behaviour of the two prion proteins, four isogenic strains were constructed that differed only by the presence or absence of the [PSI + ] and/or [URE3] determinants. As previously described (Patino et al., 1996) , Sup35p was largely found in the 100 000 g supernatant when the crude extract was prepared from a [ 
DISCUSSION
Previous cellular studies using Ure2p-GFP fusions have suggested that the [URE3] determinant is a highly aggregated form of Ure2p. Using a fusion of full-length Ure2p with GFP, we selected a bona fide [URE3] mutant of the EG12 strain, which fulfils all the genetic criteria for the prion determinant. However, when analysed by fluorescence microscopy, this [URE3] mutant did not exhibit any large aggregates. This was not due to the inability of our GFP construct to monitor the presence of Ure2p-GFP aggregates per se, since these were found in YHE64 [URE3] strain transformed with this construct (Edskes et al., 1999) . This lack of visible aggregation was also observed in a recent study that focused on an unusual allele of URE2 that induces [URE3] at high frequency (Fernandez-Bellot et al., 2000) .
Aggregation was observed in the EG12 strain when the Ure2p-GFP protein was overexpressed; but, when individual colonies were tested for the [URE3] phenotype, no correlation between the aggregation of Ure2p-GFP and the presence of the [URE3] prion phenotype could be established. Furthermore, expression of the Ure2p prion-forming domain greatly increased [ure3°]) were fractionated by centrifugation at 100 000 g. An identical volume of total extract (T), precipitated (P) and soluble (S) fractions was loaded onto a 10% SDS-PAGE. After transfer onto nitrocellulose membranes, the proteins were detected using affinity-purified Sup35p (upper panel) and Ure2p (lower panel) antibodies. 
Speculation
Based on our findings, we propose a new scheme for the replication of the [URE3] determinant ( Figure 5 ). This model is compatible with the nucleated conformational conversion model proposed by Serio et al. (2000) and is based upon the assumption that both the macro-aggregation of Ure2p and [URE3] propagation are, in some way, related but do not necessarily correspond to the same state of Ure2p. The conditions under which Ure2p aggregation may be observed are also favourable for the formation of [URE3], as is the case when overexpressing Ure2p or its N-terminal prion-forming domain. We propose that Ure2p exists in equilibrium with a Ure2p* isoform. This Ure2p* isoform would self-aggregate more easily than Ure2p itself, giving rise to either amorphous aggregates or to more organized structures such as the amyloid fibres that have been observed in vitro (Taylor et al., 1999; Thual et al., 1999 ). In our model, the Ure2p* species could also give rise to another Ure2p species (Ure2p [URE3] ) or, alternatively, it could be Ure2p [URE3] itself. This isoform, which does not sediment at 100 000 g centrifugation, would correspond to the form of the prion protein that has the characteristic self-propagating properties and could comprise a smaller non-pelletable aggregate. When Ure2p is overexpressed, the overall concentration of Ure2p increases, leading to a higher level of proteins taking up the Ure2p* state. As a consequence, the protein would either aggregate or remain infectious and essentially soluble. Once this state is reached, the cells become [URE3]. It is important to note that, in this case, the mechanism of [URE3] formation is not due to the formation of a large structure that can be observed with the GFP-based assay. However, these structures may be observed more often than in the wild-type cells, since they would be in equilibrium with Ure2p*.
The balance between the soluble and the aggregated forms of the Ure2p protein in a given strain is probably influenced by the genetic background of that strain. A pathway could exist (see Figure 5 ) that would give rise to large Ure2p aggregates with previously formed Ure2p [URE3] . Such a 'dead-end product' would be formed less efficiently in the genetic background used in our study (see also Fernandez-Bellot et al., 2000) compared to the strains described by others (Edskes et al., 1999) .
METHODS
Strains.
The following strains of Saccharomyces cerevisiae were used in this study. MATα, 112, 15, ΔURA2::HIS3 CC34a: MATα, 112, 15,  MATα, 112, 15 Δtrp1, ade2-1, leu2-3, 112, his3-11,15 Δura2::HIS3, URE2::GFP-TRP1 BMA64-1b MATa; Δtrp1, 112, 15 W9: MATa, SUQ5, SUQ5, 112, SUQ5, 112, SUQ5, 112, SUQ5, 112, 
CC30:
ΔURA2::HIS3, [URE3] CC34α:; ΔURA2 [PSI + ] CW7a MATa,1; Δ URA2::HIS3 [URE3] CW9a MATa,1; Δ URA2::HIS3 [PSI + ] CW10a MATa,
Construction of plasmids.
The multi-copy plasmid pYeHFc 2L V10 URE2 was derived from the plasmid pYeHFc 2L URE2 originally described by Komar et al. (1998) as follows. A BamHIBglII fragment containing the PGK1 promoter was obtained from the pYeV10 vector (Cullin and Pompon, 1988) and inserted into the unique BamHI restriction site. The prion domain (1-65) of URE2 was PCR amplified and cloned in pYeHFc 2L.
The BamHI-AatII cassette, containing a GFP fragment, obtained from pYeGC2U (J.M. Rouillard, unpublished data) was then inserted in pYeHFC 2L V10 URE2. The amino-acid sequence of the Ure2p-GFP fusion protein expressed by these vectors is given below, with the Ure2 protein sequence indicated in bold and the GFP sequence underlined.
MMNNNGNQVSNLSNALRQVNIGNRNSNTTTDQSNINFEFST-GVNNNNNNNSSSNNNNVQNNNSGRNGSQNNDNEN-
The single-copy plasmid pYeHFc 1L URE2 was constructed by gap repair, replacing the 2μ-LEU2 DNA fragment of pYeHFc 2L V10 URE2 with an ARS CEN-LEU2 insert. Microscopy techniques. Cells were usually cultured in 10 ml of an appropriate liquid growth medium. Three millilitres of the medium were removed and 3 μl of a solution of 4 μg/μl bisbenzimide (Hoechst, Sigma) were added. After incubation for 15 min at 30°C, cells were pelleted and washed twice in sterile water. The cell pellets were then resuspended in a 50 μl Dabco solution [218 mM diazabicyclo 2-2-2 octane (Sigma), 25% (v/v) PBS buffer, 75% (v/v) glycerol]. Cells were photographed using a DMRB microscope (Leica, Germany) with a PL APO 63 objective. Protein extraction and fractionation. The four isogenic strains CW7a, CW8a, CW9a and CW10a, carrying various combinations of the [PSI + ] and [URE3] determinants, were grown to a cell density of ∼5 × 10 6 cells/ml in YPD. Cells were then resuspended (to a density of 3.3 × 10 8 cells/ml) in 10 mM phosphate buffer pH 7.5, 250 mM NaCl, 2 mM phenylmethylsulfonyl and one tablet of protease inhibitor cocktail (Boehringer) and disrupted with glass beads at 4°C. The resulting total crude extract was fractionated by centrifugation for 15 min at 100 000 g at 4°C using a TL100 centrifuge (Beckman). The resulting supernatant was recovered, and an equal volume of buffer was added to the pellet. After incubation for 10 min at 95-100°C in 2× standard SDS-PAGE loading buffer, identical volumes (15 μl) of each fraction were loaded onto a 10% SDS-polyacrylamide gel. For western blot analysis, the proteins were transferred onto a nitrocellulose membrane and detected with affinity purified polyclonal antibodies raised against full-length, recombinant Sup35p and Ure2p, respectively.
